Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: A paired validating cohort study using template prostate mapping biopsies as the reference standard

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 1, 2014, Pages 40-46

  Abd Alazeez, M ^a,b   Kirkham, A ^a   Ahmed, H U ^a,c   Arya, M ^a,d   Anastasiadis, E ^e   Charman, S C ^f   Freeman, A ^a   Emberton, M ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Fayoum University   (Egypt)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

clinically significant disease; multiparametric MRI; prebiopsy; template prostate mapping; transrectal ultrasound guided biopsy; triage test

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BIOPSY; CANCER GRADING; COHORT ANALYSIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; COHORT STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGAN SIZE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84894053805     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.43     Document Type: Article

References (33)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
2. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
3. Taylor JA, Gancarczyk KJ, Fant GV, McLeod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002;60:841-845.
4. Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197-206.
5. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 2013;73:778-787.
6. Hu Y, Ahmed HU, Carter T, Arumainayagam N, Lecornet E, Barzell W et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012;110:812-820.
7. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-757.
8. Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012;62:986-996.
9. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-Dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007;70:27-35.
10. Simmons L, Ahmed HU, Moore CM, Emberton M. Imaging for Significant Prostate Cancer Risk Evaluation (PICTURE). ClinicalTrials.gov. 2011.
11. Emberton M. PROMIS-Prostate MRI Imaging Study-Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer. ClinicalTrials.gov, 2011.
12. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-1242.
13. Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 2011;35:1351-1355.
14. Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186:458-464.
15. Efron B, Tibshirani RJ. Monographs on Statistics and Applied Probability: An Introduction to the Bootstrap. Chapman and Hall/CRC, 1994.
16. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009;74:1094-1099.
17. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2011;77:340-345.
18. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011;186:1818-1824.
19. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-152.
20. Isebaert S, Van den Bergh L, Haustermans K, Joniau S, Lerut E, De Wever L et al. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging 2013;37:1392-1401.
21. Akin O, Gultekin DH, Vargas HA, Zheng J, Moskowitz C, Pei X et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011;21:1970-1978.
22. Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 2011;14:232-237.
23. Kirkham A, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163-1175.
24. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012;13:622-632.
25. Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012;188:2152-2157.
26. Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011;108(8 Pt 2):E171-E178.
27. Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 2013;189:860-866.
28. Delongchamps NB, Peyromaure M, Schull A, Beuvon F, Bouazza N, Flam T et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol 2013;189:493-499.
29. Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multiparametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int 2011;87:49-53.
30. Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathologic features of prostate cancer detected on transperineal template-guided mapping biopsy following negative transrectal ultrasound-guided biopsy. J Urol 2013;190:509-514.
31. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361:1704-1706.
32. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M-O et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303.
33. Wolters T, Roobol MJ, PJv Leeuwen, RCNvd Bergh, Hoedemaeker RF, Leenders GJLHv et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121-125.